OBJECTIVES: HPV genotypes 16/18 are the most prevalent worldwide and are present in around 70% of all cervical cancer (CxCa) cases. This analysis aims to estimate clinical and economic impact of the implementation of HPV 16/18 genotyping test for CxCa primary screening at Mexican Institute of Social Security (IMSS) that is the main healthcare provider covering around 50% of Mexican population. METHODS: A cohort Markov model with a five-year time horizon was developed. A 300,000 women cohort was simulated since payer perspective. Two scenarios were evaluated: 1) cytology screening, where women are re-tested for ASCUS, ≥CIN1 are referred to colposcopy, cycle lenght is 1-year, if negative 3 consecutive cycles length changes to 2-years; 2) primary screening HPV genotyping, women HPV-16/18 are referred to colposcopy, other 12 high-risk HVP genotyping are referred to cytology with 12-months follow-up, and when negative a follow-up in 3-year cycle.  Clinical and test performance data were taken from ATHENA trial and other published sources. Direct medical costs for cytology and CxCa treatments were obtained from local published sources. Costs for HPV genotyping test was given by the manufacturer. Costs are expressed in 2015 USD ($1USD=$15MXN).  RESULTS: Due to cobas HPV genotyping sensibility, total number of CxCa cases would be 46% lower (221 vs 409, respectively) and would result in 44% less mortality events (8 vs 15, respectively) compared to cytology. To have comparable cycles for both strategies a three-year time horizon was used for cost comparison. Total screening costs were 26% lower for HPV genotyping and only 21% higher for treatment costs, resulting in total savings of 1.6 million over cytology. CONCLUSIONS: Compared to cytology, incorporation of cobas HPV genotyping test as primary screening for CxCa at IMSS represents during the first-cycle potential savings of 10% as an improvement in clinical benefits, such as reduction in the incidence and mortality due to CxCa.